Eli Lilly's Jaypirca approved as first-line CLL therapy
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
The Food and Drug Administration has approved Eli Lilly's drug Jaypirca as a first-line treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma, expanding its therapeutic use to previously untreated patients.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu